Loading viewer...
investor_presentation
Format: PDF investor_presentation
| SLIDE 1 NASDAQ: XENE | www.xenon -pharma.com Corporate Presentation December 2019
NASDAQ: XENE | www.xenon -pharma.com
Corporate Presentation
December 2019| SLIDE 2Forward Looking Statement/Safe Harbor
This presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertainties and assumptions. If the risks
or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward -
looking statements. All statements other than statements of historical fact could be deemed forward -looking, including, but not limited to, statements
regarding our expectations regarding the timing of and results from clinical trials and pre -clinical development activities, inc luding those related to XEN1101,
XEN496, XEN007 and our other product candidates, along with those related to XEN901 and other pre -clinical compounds covered by our collaboration with
Neurocrine Biosciences, Inc.; the potential efficacy, safety profile, future development plans, addressable market, regulator y success and commercial
potential of XEN1101, XEN496, XEN007 , XEN901 and other product candidates, the anticipated timing of IND, or IND equivalent, submissions and the
initiation of future clinical trials for XEN1101, XEN496, XEN007, XEN901 and other product candidates, the efficacy of clinic al trial designs, our ability to
successfully develop and achieve milestones in the XEN1101, XEN496 , XEN007, XEN901 and other development programs, the desig n of clinical trials and
anticipated enrollment, and the progress and potential of other ongoing development programs.
These statements are based on estimates and information available to us at the time of this presentation and are not guarante es of future performance.
Actual results could differ materially from our current expectations as a result of many factors, including but not limited t o promising results in early clinical
trials may not be replicated in subsequent clinical trials; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product
candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed
to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered p rograms; the impact of
competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities
and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. Except as required by law, w e assume no obligation and
do not intend to update these forward -looking statements or to conform these statements to actual results or to changes in our e xpectations.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. Al l other trademarks belong to
their respective owner.
Preview truncated — download the full document for the complete content.
investor_presentation
15 Pages
investor_presentation
23 Pages
Unknown